LMC Diabetes & Endocrinology Ltd.
lmc.caTotal trials
21
Active
4
Phase 3
0
Total enrollment
23,929
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 1 of 1 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Semaglutide | — | — | — | — | — | 2 |
Next readouts
- 2026-04
Top conditions
- Type 2 Diabetes7
- Diabetes Mellitus, Type 23
- Diabetes Mellitus, Type 13
- Type 2 Diabetes Mellitus2
- Diabetes Mellitus2
- Glucose1
- Nonalcoholic Steatohepatitis1
- Type1diabetes1
Frequently asked questions about LMC Diabetes & Endocrinology Ltd.
- How many clinical trials does LMC Diabetes & Endocrinology Ltd. have on ClinicalTrials.gov?
- LMC Diabetes & Endocrinology Ltd. is listed as the lead sponsor on 21 clinical trials in ClinicalTrials.gov, 4 of which are currently active (recruiting, enrolling, or ongoing).
- How many of LMC Diabetes & Endocrinology Ltd.'s trials are in Phase 3?
- 0 of LMC Diabetes & Endocrinology Ltd.'s trials are in Phase 3, spread across 1 active drug program.
- What therapeutic areas does LMC Diabetes & Endocrinology Ltd. focus on?
- LMC Diabetes & Endocrinology Ltd.'s most-studied conditions on ClinicalTrials.gov are Type 2 Diabetes, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Type 2 Diabetes Mellitus, Diabetes Mellitus.
- When are LMC Diabetes & Endocrinology Ltd.'s next clinical trial readouts?
- LMC Diabetes & Endocrinology Ltd. has 1 upcoming primary-completion readout tracked here; the soonest is “Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes”, expected around 2026-04.